title: [Long-acting insulins in the treatment of type 2 diabetes: a hard choice].
authors.affiliation: Zentrum für Diabetes- und Stoffwechselerkrankungen, m&i-Fachklinik Bad Heilbrunn, Wörnerweg 30, D-83670, Bad Heilbrunn, Deutschland, andreas.liebl@fachklinik-bad-heilbrunn.de.
authors.forename: Andreas
authors.initials: A
authors.lastname: Liebl
mesh_terms: D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D000069057:Insulin Detemir; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000009:adverse effects; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069057:Insulin Detemir; D007336:Insulin, Isophane; D049528:Insulin, Long-Acting; C517652:hemoglobin A1c protein, human; C571886:insulin degludec